Emcure Pharmaceuticals Ltd. has announced the commercial launch of Poviztra®, a semaglutide injection, for chronic weight management across India. With this launch, Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra®, the second brand of Novo Nordisk’s semaglutide injection for weight management in the country.
Poviztra® is available as a once-weekly injectable pen in five dosage strengths—0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a maintenance dose of 2.4 mg. The therapy is priced starting at ?8,790 per month for four weekly doses and is delivered through a state-of-the-art pen device designed for ease of use and precise dosing.
The semaglutide formulation is supported by extensive clinical evidence from the STEP and SELECT clinical trial programmes and has demonstrated strong real-world effectiveness. Globally, the molecule has nearly a decade of market presence, with around 38 million patient-years of exposure, backed by a robust safety and efficacy profile.
Poviztra® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for adults with obesity (BMI =30 kg/mý) or overweight (BMI =27 kg/mý) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. Clinical studies have shown weight loss of more than 20% in many patients.
Commenting on the launch, Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, said the introduction of Poviztra® comes at a critical time as India faces a growing obesity challenge. He added that Emcure aims to expand equitable access to scientifically validated weight-management therapies through its strong distribution network and pan-India reach.
With this launch, Emcure Pharmaceuticals reaffirmed its commitment to improving patient access to innovative treatments and addressing the increasing burden of overweight and obesity-related health conditions in India.